PECULIARITIES OF CULTIVATION OF HAEMOPHILUS INFLUENZAE TYPE B STRAINS - PRODUCERS OF POLYRIBOSYLRIBITOL PHOSPHATE - THE MAIN COMPONENT OF POLYSACCHARIDE VACCINES

One of the up-to-date challenges of modern immunobiotechnology is the development and introduction of an effective vaccine against the infection caused by the bacterium Haemophilus influenza, type b (Hib). The main active substance of the vaccine against Hib infection is the capsular polysaccharide polyribosylribitol phosphate (PRP), which is isolated from the fermentation broth of H. influenzae type b. An important technological step in obtaining PRP is the cultivation of the producer strain under conditions that allow obtaining the maximum amount of the target product. At the moment, it is planned to select the optimal conditions for cultivation of H. influenzae type b B-7884, which had been earlier isolated and identified by the employees of FSUE “Saint-Petersburg scientific research institute of vaccines and serums and the enterprise for the production of bacterial preparations” of FMBA, Russia. The analysis of literature data concerning the cultivation of H. influenzae type b was made in order to identify the main factors influencing the biosynthesis of PRP.

The aim of the investigation is to analyze and summarize the literature data on the cultivation peculiarities of haemophilus influenzae of b-type strains.

Materials and methods. In the process of selecting the material for writing this review article. The databases of Google Patents, Science Research Portal, Google Scholar, ScienceDirect, CiteSeer Publications ResearchIndex, Ingenta, PubMed, KEGG, etc. were used.

Results and discussion. As a result of the literature analysis, the main factors influencing the PRP biosynthesis were identified: the nature and concentration of carbon and nitrogen sources in the growth medium, the concentration of growth factors (nicotinamide adenine dinucleotide, hemin, vitamins), additional feed, pH adjustment during cultivation, stirring speed. The data of PRP-producing strains and the conditions of their cultivation have been summarized, as well as the amount of synthesized PRP, which essentially depends on both the physiological capabilities of the biological agent and the factors effecting the regulation of metabolism.

Conclusion. The results of this work will be taken into account in carrying out the researches for optimization of H. influenzae type b B-7884 strain cultivation conditions.

1. Almeida AF, Trindade E, B Vitor A, Tavares M. Haemophilus influenzae type b meningitis in a vaccinated and immunocompetent child. J Infect Public Health. 2017 May-Jun;10(3):339–42. DOI: 10.1016/j.jiph.2016.06.001.

2. Sakata H, Adachi Y, Morozumi M, Ubukata K. Invasive Haemophilus influenzae infections in children in Kamikawa subprefecture, Hokkaido, Japan, 2006-2015: The effectiveness of H. influenzae type b vaccine. J Infect Chemother. 2017 Jul;23(7):459–62. DOI: 10.1016/j.jiac.2017.03.019.

3. Wood N, Menzies R, McIntyre P. Epiglottitis in Sydney before and after the introduction of vaccination against Haemophilus influenzae type b disease. Intern Med J. 2005 Sep;35(9):530–5. DOI: 10.1111/j.1445-5994.2005.00909.x.

4. Slack MPE. A review of the role of Haemophilus influenzae in community-acquired pneumonia. Pneumonia. 2015;6(1):26–43. DOI.org/10.15172/pneu.2015.6/520.

5. Kelly DF, Moxon ER, Pollard AJ. Haemophilus influenzae type b conjugate vaccines. Immunology. 2004 Oct;113(2):163–74. DOI: 10.1111/j.1365-2567.2004.01971.x.

6. Briere EC, Rubin L, Moro PL, Cohn A, Clark T, Messonnier N. Prevention and control of Haemophilus influenzae type b disease: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2014 Feb 28;63(RR-01):1–14.

7. Davis S, Feikin D, Johnson HL. The effect of Haemophilus influenzae type b and pneumococcal conjugate vaccines on childhood meningitis mortality: a systematic review. BMC Public Health. 2013;13 Suppl 3:S21. DOI: 10.1186/1471-2458-13-S3-S21.

8. Chongmelaxme B, Hammanee M, Phooaphirak W, Kotirum S, Hutubessy R, Chaiyakunapruk N. Economic evaluations of Haemophilus influenzae type b (Hib) vaccine: a systematic review. J Med Econ. 2017 Oct;20(10): 1094–106. DOI: 10.1080/13696998.2017.1359181.

9. Howie SRC, Oluwalana C, Secka O, Scott S, Ideh RC, Ebruke BE, Balloch A, Sambou S, Erskine J, Lowe Y, Corrah T, Adegbola RA. The effectiveness of conjugate Haemophilus influenzae type b vaccine in the Gambia 14 years after introduction clinical infectious diseases. Clin Infect Dis. 2013 Dec;57(11):1527–34. DOI: 10.1093/cid/cit598.

10. Otczyk DC, Cripps AW Vaccination for the control of childhood bacterial pneumonia – Haemophilus influenzae type b and pneumococcal vaccines. Pneumonia. 2013;2(1):2–15. DOI: 10.15172/pneu.2013.2/229.

11. Arvas A, Gur E, Bahar H, Torun MM, Demirci M, Aslan M, Kocazeybek B. Haemophilus influenzae type b antibodies in vaccinated and non-vaccinated children. Pediatr Int. 2008 Aug;50(4):469–73. DOI: 10.1111/j.1442-200X.2008.02591.x.

12. World Health Organization: Recommendations for the production and control of Haemophilus influenzae type b conjugate vaccines. WHO Technical Report Series [Internet]. 2000. N 897. [cited 2017 Aug 01]. Available from: http://www.who.int/biologicals/publications/trs/areas/vaccines/haemophilus/en/

13. Salimova EL, Konon AD, Truhin VP, Petrovskii SV, Krasilnikov IV. Haemophilus influenzae SPB tip b V-7884 proizvodstvennyj shtamm polisaharidnyh vakcin [Haemophilus influenzae SPB type b V-7884 – master seed strain of polysaccharide vaccines]. Actual biotechnology. 2016;3(18):77–81. Russian.

14. Trukhin VP, Petrovskii SV, Krasilnikov IV, Nacharova EP, Yevtushenko AE, Salimova EL, Konon AD, Ujba SV, inventor; SHtamm Haemophilus influenzae SPB tip v vysokoaktivnyj producent kapsulnogo polisaharida poliribozilribitolfosfata [The Haemophilus influenzae SPB type b strain is a highly active producer of the capsular polysaccharide polyribosyl ribitol phosphate]. Russian Federation RU 2624014. 2017 Jun 30. Russian.

15. da Silva MR, Andreia Freixo Portela C, Maria Ferreira Albani S, Rizzo de Paiva P, Massako Tanizaki M, Zangirolami TC. Experimental design and metabolic flux analysis tools to optimize industrially relevant Haemophilus influenzae type b growth medium. Biotechnol Prog. 2017 Aug 25. DOI: 10.1002/btpr.2546.

16. Anderson P, Pitt J, Smith DH. Synthesis and release of polyribophosphate by Haemophilus influenzae type b in vitro. Infect Immun. 1976 Feb;13(2):581–9.

17. Hamidi A, Beurret MF, inventor; De Staat Der Nederlanden, Vert. Door De Minister Van Vws, assignee. Process for producing a capsular polysaccharide for use in conjugate vaccines. United States patent. US 7582459 B2. 2009 Sep 1.

18. Herriott RM, Meyer EY, Vogt M, Modan M. Defined medium for growth of Haemophilus influenzae. J Bacteriol. 1970 Feb;101(2):513–6.

19. Wolin HL. Defined medium for Haemophilus influenzae type b. J Bacteriol. 1963 Jan;85:253–4.

20. Klein RD, Luginbuhl GH. Simplified media for the growth of Haemophilus infruenzae from clinical and normal flora sources. J Gen Microbiol. 1979 Aug;113(2):409–11.

21. Artman M, Domenech E, Weiner M. Growth of Haemophilus influenzae in simulated blood cultures supplemented with hemin and NAD. J Clin Microbiol. 1983 Aug;18(2):376–9.

22. Esmaily F, Aminian M, Tavangar AR, Hadi A Comparison of bacterial biomass and PRP production between different isolates of Haemophilus influenza type b (Hib) under different culture conditions. Archives of Razi Institute. 2011;66(1):43–9. DOI: 10.22092/ari.2016.103865.

23. Torabi M, Haadi A, Asli E, Aminian M, Esmaily F, Afshar M, Hatami A A study on Haemophilus influenzae type b growth rate and capsule production in different media. Archives of Razi Institute. 2012;67(1):7–12. DOI: 10.22092/ARI.2016.103881.

24. Takagi M, Cabrera-Crespo J, Baruque-Ramos J, Zangirolami TC, Raw I, Tanizaki MM. Characterization of polysaccharide production of Haemophilus influenzae type band its relationship to bacterial cell growth. Appl Biochem Biotechnol. 2003 Aug;110(2):91–100.

25. Takagi M, Zangirolami TC, Tanizaki MM, Cabrera-Crespo J. Improvement of simple cultivation conditions for polysaccharide synthesis by Haemophilus influenzae type b. Communicating Current Research and Educational Topics and Trends in Applied Microbiology. 2007:602–8. DOI: 10.1002/jctb.1377.

26. Cope LD, Yogev R, Muller-Eberhard U, Hansen EJ. A gene cluster involved in the utilization of both free heme and heme: hemopexin by Haemophilus influenzae type b. J Bacteriol. 1995 May;177(10):2644–53. DOI: 10.1128/jb.177.10.2644-2653.1995.

27. Wong JC, Holland J, Parsons T, Smith A, Williams P. Identification and characterization of an iron-regulated hemopexin receptor in Haemophilus influenzae type b. Infect Immun. 1994 Jan;62(1):48–59.

28. Ella KM, Ramasamy V, Naidu MG, Sarma AD, inventor; Bharat Biotech International Limited, assignee. Non-alcoholic vaccine compositions free from animal-origin and process for preparation thereof. World intellectual property organization WO 2014009971 (A2). 2014 Jan 16.

29. Takagi M, Cabrera-Crespo J, Zangirolami TC, Raw I, Tanizaki MM Improved cultivation conditions for polysaccharide production by H. influenzae type b. Journal of Chemical Technology & Biotechnology. 2006;81(2):182–8. DOI: 10.1002/jctb.1377.

30. Maitre-Wilmotte G, Speck D, Rokbi B, inventor; Sanofi Pasteur Sa, assignee. Culture medium for Haemophilus influenzae type b. United States patent US 8673617 B2. 2014 Mar 18.

31. Hir JL, Loubiere P, Barbirato F, Lindley N, inventor; Sanofi Pasteur, assignee. Method for producing Haemophilus Influenzae type b antigens. United States patent US 9556464 (B2). 2017 Jan 31.

32. Babel W. Bewertung von Substraten fur das mikrobielle Wachstum auf der Grundlage ihres Kohlenstoff/Energie-Verhaltnisses. Z. Allg. Mikrobiol. 1979;19:671–7. DOI: 10.1002/jobm.19790190910.

33. Hagman M, Nielsen JL, Nielsen PH, Jansen Jl. Mixed carbon sources for nitrate reduction in activated sludge-identification of bacteria and process activity studies. Water Res. 2008 Mar;42(6-7):1539–46. DOI: //doi.org/10.1016/j.watres.2007.10.034.

34. Fonseca RR, Silva AJ, De França FP, Cardoso VL, Sérvulo EF. Optimizing carbon/nitrogen ratio for biosurfactant production by a Bacillus subtilis strain. Appl Biochem Biotechnol. 2007 Apr;137-140(1-12):471–86. doi: 10.1007/s12010-007-9073-z.

35. Kuttiraja M, Douha A, Valéro JR, Tyagi RD. Elucidating the effect of glycerol concentration and C/N ratio on lipid production using Yarrowia lipolytica SKY7. Appl Biochem Biotechnol. 2016 Dec;180(8):1586–600.

36. Nojoomi F, Nahid AP. Effect of culture media and their ingredients on PRP production by Haemophilus influenzae. International Journal of Current Microbiology and Applied Sciences. 2014;3(11):920–5.

37. Ronald M Atlas Handbook of Microbiological Media. Third Edition: CRC Press; 2004.

38. Hamidi A, Kreeftenberg H, V D Pol L, Ghimire S, V D Wielen LA, Ottens M Process development of a new Haemophilus influenzae type b conjugate vaccine and the use of mathematical modeling to identify process optimization possibilities. Biotechnol Prog. 2016 May;32(3):568–80. DOI: 10.1002/btpr.2235.

39. Yeruva S, Mantha S, Tirumalaraju A, Rokkam SR Screening of medium components for polyribosylribitol phosphate productionby Haemophilus influenzae type-b using Plackett-Burman design. Journal of Cell & Tissue Research. 2010 Dec;10(3):2349–52.

40. Momen SB, Siadat SD, Akbari N, Ranjbar B, Khajeh K Applying central composite design and response surface methodology to optimize growth and biomass production of Haemophilus influenzae type b. Jundishapur J Microbiol. 2016 Mar 1;9(6):e25246. DOI: 10.5812/jjm.25246.

41. Nojoomi F, Siadat SD, Salmanian AH, Khoramabadi N. Improvement of large-scale PRP production by Haemophilus influenzae type b, using modified CY medium. J Fasa Univ Med Sci. 2012;1(4):182–6.

42. Arsang A, Tabatabaie A, Vaziri F, Nejati M, Zolfaghari MR, Fateh A, Jamnani FR, Bahrmand AR, Siadat SD. Optimization of large scale production of Haemophilus influenzae type b polyribosyl-ribitol phosphate. Minerva Biotecnologica. 2017 March;29(1):17–23. DOI: 10.23736/S1120-4826.16.01855-3.

43. Yagovkin EA, Vachaev BF, Shepelev AP, Golovina SV, Aleshnya VV, Medunitsyn NV, Chuprynina RP, Nemirovskaya TI, Khramova NI, inventor. Sposob polucheniya antigennogo preparata Haemophilus influenzae tipa b (Hib) [A method for producing an Haemophilus influenzae type b (Hib) antigenic preparation]. Russian Federation RU 2185191. [Internet] 2002 Jul 20. [cited 2017 Aug 01]. Available from: http://www1.fips.ru/fips_servl/fips_servlet?DB=RUPAT&DocNumber=2185191&TypeFile=html. Russian.

44. Vaneeva NP, Elkina SI, Aparin PG, inventor. SHtamm bakterij Haemophilus influenzae V 326 stabilnyj producent kapsulnogo polisaharida [Strain of bacteria Haemophilus influenzae B No. 326, stable producer of capsular polysaccharide]. Russian Federation RU 2465316. 2012 Oct 27. Russian.

45. Elkina SI, Sergeev VV, Vaneeva NP, Aparin PG, Lvov VL, Yastrebova NE, Orlova OE, inventor. SHtamm Haemophilus influenzae B MECH No 1 producent kapsulnogo polisaharida poliribozilribitolfosfata [Strain Haemophilus influenzae B MECH No. 1 – producer of capsular polysaccharide – polyribosylribitol phosphate]. Russian Federation RU 2257412. 2005 Jul 27. Russian.

46. Elkina S.I, Vaneeva NP, Aparin PG, Lvov VL, Orlova OE, Yastrebova NE, inventor. Pitatelnaya sreda dlya kultivirovaniya bakterij Haemophilus influenzae tipa b [A growth medium for the cultivation of Haemophilus influenzae type b bacteria]. Russian Federation RU 2258737. 2005 Aug 20. Russian.

47. Orlova OE, Vaneeva NP, L’vov VL, Iastrebova NE, Elkina SI, Sergeev VV, Kalina NG, Zakharova NE Cultivation of Haemophilus influenzae, serotype B, in amino peptide-based semisynthetic nutrient medium. Zh Mikrobiol Epidemiol Immunobiol. 2002 May–Jun;(3):56–8.

48. Orlova OE Dynamics of growth of Haemophilus influenzae serotype B and synthesis of capsular polysaccharide in the process of cultivation in a synthetic nutrient medium. Zh Mikrobiol Epidemiol Immunobiol. 2002 MarApr;(2):75–7.

49. Orlova OE, Elkina SI, Iastrebova NE, Vaneeva NP, Sergeev VV, Kalina NG, Tokarskaia MM. Influence of nicotinamide adenine dinucleotide and hemin concentrations on the growth of Haemophilus influanzae type b and the synthesis of capsular polysaccharide. Zh Mikrobiol Epidemiol Immunobiol. 2005 Jul–Aug;(4):12–5.

50. Lance Gordon K, inventor; Connaught Lab, assignee. Haemophilus influenzae b polysaccharide exotoxoid conjugate vaccine. World intellectual property organization WO 8400300 (A1). 1984 Feb 2.